Mpp Pharma
United States Updated 9 July 2026
Mpp Pharma is a finished-dose manufacturer based in United States. It appears in 23 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 20 September 2024 as VAI.
1
registered plants
1 with an FDA FEI number
23
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 20 September 2024 VAI US FDA
- 13 September 2024 VAI US FDA
- 21 April 2021 VAI US FDA
- 4 April 2016 NAI US FDA
- 19 February 2014 VAI US FDA
- 30 January 2013 VAI US FDA
- 5 November 2010 VAI US FDA
- 1 December 2009 OAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Kansas City, United States | 1930436 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 23 | 1 |
Comparing suppliers?
Choose your molecules and target markets. Mpp Pharma comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- 1 active litigation matter is on record.
- The most recent inspection outcome was VAI, on 20 September 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates